Sage Therapeutics: Increasing Price Target To $84.

SAGE

Sage Therapeutics (NASDAQ:SAGE) released phase 2a data of oral SAGE-217 (a novel neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes) in the treatment of major depressive disorder ((MDD)).

(Sage Therapeutics, com...

Sage Therapeutics (NASDAQ:SAGE) released phase 2a data of oral SAGE-217 (a novel neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes) in the treatment of major depressive disorder ((MDD)).

(Sage Therapeutics, com...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics